AxoGen (AXGN) Scheduled to Post Quarterly Earnings on Thursday

AxoGen (NASDAQ:AXGN) is set to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.11. The company had revenue of $42.92 million for the quarter, compared to analysts’ expectations of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative return on equity of 22.38%. On average, analysts expect AxoGen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Trading Down 1.4 %

Shares of AXGN stock opened at $6.87 on Thursday. The company’s 50-day moving average price is $8.49 and its 200-day moving average price is $7.35. The company has a current ratio of 2.89, a quick ratio of 2.14 and a debt-to-equity ratio of 0.71. The stock has a market cap of $300.14 million, a price-to-earnings ratio of -13.21 and a beta of 1.03. AxoGen has a twelve month low of $3.45 and a twelve month high of $10.83.

Wall Street Analyst Weigh In

AXGN has been the topic of several recent research reports. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $12.00 price target on shares of AxoGen in a research report on Friday, January 19th.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Gregory Gene Freitag sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $9.00, for a total value of $225,000.00. Following the transaction, the director now owns 271,594 shares of the company’s stock, valued at $2,444,346. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other AxoGen news, VP Michael Patrick Donovan sold 36,310 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $8.81, for a total transaction of $319,891.10. Following the sale, the vice president now directly owns 35,708 shares in the company, valued at $314,587.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gregory Gene Freitag sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $9.00, for a total transaction of $225,000.00. Following the sale, the director now owns 271,594 shares in the company, valued at $2,444,346. The disclosure for this sale can be found here. Insiders have sold 111,201 shares of company stock valued at $928,054 over the last 90 days. 7.21% of the stock is owned by insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.